Results 21 to 30 of about 2,682 (215)
Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus [PDF]
Diabetes & Metabolism Journal, 2021 Background Using real-world data, cardiovascular safety was investigated in metformin users newly starting sodium glucose cotransporter 2 (SGLT2) inhibitors compared with other glucose-lowering drugs in Korea.
Ja Young Jeon +2 more
doaj +1 more source
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?
Medicina, 2023 There is a need for innovative pharmaceutical intervention in light of the increasing prevalence of metabolic disease and cardiovascular disease. The kidneys’ sodium-glucose cotransporter 2 inhibitors (SGLT2) receptors are targeted to reduce glucose ...
Munteanu Madalina Andreea +6 more
doaj +1 more source
Frontiers in Pharmacology, 2021 Several large clinical trials have shown renal and cardioprotective effects of sodium–glucose cotransporter 2 (SGLT2) inhibitors in diabetes patients, and the protective mechanisms need to be elucidated.
Kazuhiko Fukushima +3 more
doaj +1 more source
Scientific Reports, 2021 Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown impressive effects in reducing major vascular events in several randomized controlled trials (RCTs).
Wen-Hsuan Tsai +7 more
doaj +1 more source
Renoprotective Effects of SGLT2 Inhibitors
Heart Failure Clinics, 2022 SGLT2 inhibitors can protect the kidneys of patients with and without type 2 diabetes from failing. This includes blood glucose dependent and independent mechanisms. SGLT2 inhibitors lower glomerular pressure and filtration, thereby reducing the physical stress on the filtration barrier and the oxygen demand for tubular reabsorption.
openaire +4 more sources
Kidney & Blood Pressure Research, 2023 Background: Sodium-glucose cotransport protein 2 (SGLT2) inhibitors, a new type of glucose-lowering drug, have been well proved in several clinical studies for their glucose-lowering and nephroprotective effects, and the nephroprotective effects include ...
Jinfang Song, Xia Li, Jiang Ni
doaj +1 more source
CARDIOPROTECTIVE PROPERTIES OF SGLT2-INHIBITORS [PDF]
Archiv EuromedicaDue to its high mortality rate, heart failure (HF) presents a substantial worldwide health burden that calls for efficient treatment approaches. Inhibitors of the sodium-glucose co-transporter 2 (SGLT2) have become essential treatments for heart failure in all left ventricular ejection fraction (LVEF) levels.
Karol Wielgus +9 more
openaire +1 more source
Journal of Clinical and Translational Science, 2022 OBJECTIVES/GOALS: Clinical trials of SGLT2 inhibitors in patients with heart failure (HF) have confirmed a reduction in hospitalization and death. Adoption of novel therapeutics has been slower in Black and female patients. We investigated utilization of
Apoorva Gangavelli +5 more
doaj +1 more source
Navigating the therapeutic landscape of SGLT2 inhibitors in diabetes management: exploring efficacy and emerging concerns [PDF]
Exploration of MedicineSodium-glucose cotransporter 2 (SGLT2) inhibitors are integral to diabetes treatment, facilitating renal glucose excretion and offering benefits in cardiovascular risk reduction, kidney function preservation, and weight management.
Farazul Hoda +8 more
doaj +1 more source
Diabetes & Vascular Disease Research, 2022 Background The association of the use of sodium-glucose cotransporter 2 (SGLT2) inhibitor and incident dementia remains unclear. This study aimed to evaluate the risk of incident dementia with the use of SGLT2 inhibitor.
Wun-Zhih Siao +4 more
doaj +1 more source